In this week's Industry Focus, our analysts discuss their favorites of the successful 2014 healthcare large-cap stocks.
Both AbbVie and Zoetis offer something for healthcare investors.
The 10 largest hedge funds bought nearly $16 billion worth of stocks in the third quarter, and three of them were their favorites.
There's more to top dividend-paying stocks than the yield.
Three Motley Fool analysts tell investors which three companies they think would be ripe for an acquisition.
Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?
Three Motley Fool analysts tell investors what they believe are the year's most memorable events in the healthcare sector.
Pfizer's third-quarter earnings report looked rather tame unless you dug into its quarterly conference call. Here are the five key things Pfizer's management wants you to know about where the company is headed next.
Just because you own Allergan doesn't mean you should necessarily own Actavis.
Hint: Ebola isn't on the list. But you might be surprised what is.